Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Curcumin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.89 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.89 |
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 0.89 |
| ▸ | APP | P05067 | 10/20 | 0.89 |
| ▸ | MAPT | P10636 | 9/20 | 0.89 |
| ▸ | BACE1 | P56817 | 5/20 | 0.89 |
| ▸ | MMP9 | P14780 | 4/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.89 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.89 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.89 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.89 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.89 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.89 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.89 |
| ▸ | STAT3 | P40763 | 2/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Curcumin SCHEMBL290797 | 1.00 | APP (0.89) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL27712113 | 0.99 | APP (0.86) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL2334244 | 0.96 | APP (0.82) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL8336603 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL8440 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL17629819 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL6901740 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL250984 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL2804734 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL17629818 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022257986-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| US-20250295615-A1 | COMBINATIONS OF CURCUMIN AND URSOLIC ACID AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-09-25 | — | — | US | disclosed |
| EP-4433174-A1 | COMBINATIONS OF CURCUMIN AND URSOLIC ACID AND USES THEREOF | Board of Regents, The University of Texas System (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023091668-A1 | COMBINATIONS OF CURCUMIN AND URSOLIC ACID AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4045012-A1 | SELF-MICROEMULSIFYING MULTI-DELIVERABLE SYSTEMS | Quicksilver Scientific, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220079882-A1 | COMPOSITIONS AND METHODS FOR INCREASING THE BIOAVAILABILITY OF ONE OR MORE COMPOUNDS | BOSTON BIOPHARM INC. | 2022-03-17 | — | — | US | disclosed |
| US-11185507-B2 | Compositions and methods for increasing the bioavailability of one or more compounds | BOSTON BIOPHARM INC. (US) | 2021-11-30 | — | — | US | disclosed |
| CN-110327315-A | The purposes of curcumin derivate | 中国科学院成都生物研究所 | 2019-10-15 | — | — | CN | disclosed |
| US-20170304204-A1 | COMPOSITIONS AND METHODS FOR INCREASING THE BIOAVAILABILITY OF ONE OR MORE COMPOUNDS | BOSTON BIOPHARM INC. | 2017-10-26 | — | — | US | disclosed |
| CN-106413692-A | Modified-release therapeutic systems for oral administration of curcumin in the treatment of intestinal disorders | 莫戈恩药物有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-103607993-B | Oral care composition | 荷兰联合利华有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-103607993-A | Oral care compositions | UNILEVER NV | 2014-02-26 | — | — | CN | disclosed |